MGI/SuperGen Dacogen update
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MGI and SuperGen have responded to a Sept. 1 "approvable" letter for Dacogen (decitabine), MGI says Nov. 15. The companies believe the response addresses FDA's questions regarding transfusion requirements in the Phase III trial for the myelodysplastic syndromes treatment and confirms that Dacogen met its primary endpoint...
You may also be interested in...
Dacogen deadline is May 15
MGI/SuperGen's Dacogen (decitabine) has a new PDUFA date of May 15 following FDA's acceptance of the firm's Nov. 15 response to a September "approvable" letter (1Pharmaceutical Approvals Monthly December 2005, In Brief). The firm's submission includes FDA-requested analyses regarding transfusion data for the myelodysplastic syndromes therapy...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.